

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Sodium Potassium Magnesium and Calcium Concentrated Solution (20mg) as well as Levodopa and Benserazide Hydrochloride Tablets (Levodopa 200mg and Benzserazide 50mg equivalent to Benserazide Hydrochloride 57mg) from the National Medical Products Administration of China (the “NMPA”), being under type 3 and type 4 chemical drug respectively, being the second and the fourth of such approvals for the PRC entities respectively, and both being regarded as passing the consistency evaluation. As of the date of this announcement, the Group cumulatively has generic drug products of 100 types with 133 specifications which have passed or been regarded as passing the consistency evaluation.

Sodium Potassium Magnesium and Calcium Concentrated Solution is mainly used for electrolyte supplementation in adult patients when infusing solutions containing concentrated glucose or amino acids through central venous infusion. Levodopa and Benserazide Hydrochloride Tablets are mainly used for the treatment of Parkinson's disease, Symptomatic Parkinson's syndrome (postencephalitic, arteriosclerotic or toxic) but not drug-induced Parkinson's syndrome. As stated in the Company's announcement dated 20 March 2024, the Group's Benserazide Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 13 August 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.